/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

GALECTIN THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$5.75 0.044(4.4%) GALT at 04 Dec 2025 04:32 PM Biotechnology
Lowest Today 5.54
Highest Today 5.875
Today’s Open 5.66
Prev. Close 5.46
52 Week High 6.55
52 Week Low 0.73
Day’s Range: Low 5.54 High 5.875
52-Week Range: Low 0.73 High 6.55
1 day return -
1 Week return -1.04
1 month return +0.26
3 month return +21.99
6 month return +344.14
1 year return +142.94
3 year return +381.77
5 year return +101.59
10 year return -

Institutional Holdings

Vanguard Group Inc 3.41

Vanguard Total Stock Mkt Idx Inv 2.12

Advisor Group Holdings, Inc. 1.98

BlackRock Inc 1.39

Jane Street Group LLC 1.17

Geode Capital Management, LLC 1.04

Vanguard Institutional Extnd Mkt Idx Tr 0.85

Sontag Advisory LLC 0.75

Geneos Wealth Management Inc 0.66

LPL Financial Corp 0.57

Commonwealth Equity Services Inc 0.45

Fidelity Extended Market Index 0.42

Morgan Stanley - Brokerage Accounts 0.33

State Street Corp 0.31

Sovran Advisors, LLC 0.31

Susquehanna International Group, LLP 0.30

Vivaldi Capital Management, LLC 0.27

UBS Group AG 0.26

RETIREMENT GUYS FORMULA LLC 0.25

Millennium Management LLC 0.23

Soltis Investment Advisors, LLC 0.22

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.19

Northern Trust Corp 0.19

iShares Micro-Cap ETF 0.16

Extended Equity Market Fund K 0.14

Fidelity Total Market Index 0.14

Fidelity Nasdaq Composite ETF 0.12

Fidelity Series Total Market Index 0.11

Fidelity Nasdaq Composite Index 0.11

Spartan Extended Market Index Pool F 0.10

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

Horizon Kinetics Medical ETF 0.08

NT Ext Equity Mkt Idx Fd - NL 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

Spartan Total Market Index Pool G 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Vanguard Balanced Index Inv 0.04

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.04

Vanguard U.S. Eq Idx £ Acc 0.03

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 352.06 M

PB Ratio 207.6975

PE Ratio 0.0

Enterprise Value 466.52 M

Total Assets 17.50 M

Volume 599300

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-41703000 -41.7M, FY22:-39200000 -39.2M, FY21:-30975000 -31.0M, FY20:-23516000 -23.5M, FY19:-13381000 -13.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-2000 -0.0M, Q1/2025:-10000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-9000 -0.0M

Quarterly Net worth Q3/2025:-8183999 -8.2M, Q2/2025:-7521000 -7.5M, Q1/2025:-9631000 -9.6M, Q3/2024:-11220000 -11.2M, Q2/2024:-12371000 -12.4M

Fund house & investment objective

Company Information Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Organisation Biotechnology

Employees 15

Industry Biotechnology

CEO Mr. Joel Lewis CPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow